Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout.

ABSTRACT:

Background

In previous studies, cardiovascular (CV) risk was increased in patients with gout. The effects of uric acid-lowering therapy on CV risk in gout patients have been investigated in numerous studies; however, allopurinol and benzbromarone have rarely been compared.

Objectives

To compare CV risk based on allopurinol and benzbromarone treatment in Korean gout patients.

Design

A nationwide population-based retrospective cohort study.

Methods

We used South Korea database of the Health Insurance Review and Assessment (HIRA) service to identify gout patients ⩾18 years of age who newly started allopurinol or benzbromarone between 2009 and 2015. The primary outcome of the study was the occurrence of a composite CV endpoint, which included coronary revasculariza

SUBMITTER: Eun Y 

PROVIDER: S-EPMC9373176 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature